Moderna sees no impact on Covid-19 vaccine from potential patent waiver
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
TUESDAY, MAY 17, 2022
TUESDAY, MAY 17, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Moderna sees no impact on Covid-19 vaccine from potential patent waiver

Coronavirus chronicle

Reuters
06 May, 2021, 08:50 pm
Last modified: 06 May, 2021, 08:52 pm

Related News

  • Covid vaccine maker Moderna flags Japan ambition with sumo sponsorship
  • Moderna seeks FDA authorisation for second Covid booster for all adults
  • Moderna jabs to be given as boosters instead of Pfizer
  • Moderna could be ready to develop omicron booster in weeks: CEO
  • Moderna Covid-19 vaccine patent dispute headed to court, US NIH head says

Moderna sees no impact on Covid-19 vaccine from potential patent waiver

The comments come a day after the United States said it would support waiving intellectual property rights for Covid-19 vaccines in order to help speed an end to the pandemic, paving the way for what could be months of negotiations to hammer out a specific waiver plan

Reuters
06 May, 2021, 08:50 pm
Last modified: 06 May, 2021, 08:52 pm
Moderna sees no impact on Covid-19 vaccine from potential patent waiver

Moderna Inc on Thursday said it believes countries around the globe would continue buying its Covid-19 vaccine for years even if patents on the shots are waived, noting that rivals would face significant hurdles in scaling up manufacturing.

The comments come a day after the United States said it would support waiving intellectual property rights for Covid-19 vaccines in order to help speed an end to the pandemic, paving the way for what could be months of negotiations to hammer out a specific waiver plan.

Moderna shares were off 7.5% after falling as much as nearly 12% earlier. Shares of other Covid-19 vaccine manufacturers like Pfizer Inc were also down on the patent news.

"While this is a negative headline," said Morgan Stanley analysts in a research note, there is no mechanism "to force management to teach other manufacturers how to make their vaccine, suggesting no change to the status quo."

Moderna, which said in October it would not enforce patents on its vaccine during the pandemic, noted the lack of companies able to rapidly scale up complex manufacturing of a similar vaccine to meet surging global demand.

"They will have to go run a clinical trial, get the data, get the product approved and scale manufacturing. This does not happen in 6 or 12 or 18 months," Moderna Chief Executive Stephane Bancel said on a post-earnings conference call.

Moderna has faced its own hurdles scaling up production with some shortfalls in the manufacturing supply chain, which includes Swiss contract manufacturer Lonza Group, leading to delivery delays in Europe.

Bancel said he has had to tell some countries, "we're very sorry. We have no more supply for you in 2021."

Still, the company said it expects to produce between 800 million to 1 billion doses this year.

Moderna raised its 2021 sales forecast for its Covid-19 shot by 4.3% to $19.2 billion on Thursday, two days after Pfizer increased its full-year Covid-19 vaccine sales forecast more than 70% to $26 billion.

Moderna expects vaccine output could increase to 3 billion doses in 2022 to meet demand from nations looking to stock up supplies and sign up deals for "booster" doses.

Early clinical trial data released on Wednesday showed that a third dose of either Moderna's current shot or an experimental new vaccine increases immunity against the more easily transmissible virus variants first found in Brazil and South Africa.

Moderna, which is seeking to expand authorization of its vaccine to children and adolescents, on Thursday said an initial analysis of a study in those aged 12 to 17 showed an efficacy rate of 96%.

The company also reported its first-ever quarterly profit on sales of the vaccine.

Moderna Covid-19 Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
    Dollar price crosses Tk100 in open market 
  • Finland's Prime Minister Sanna Marin speaks during the plenary session at the Finnish parliament in Helsinki, Finland on 16 May 2022. Photo: Reuters
    Finland's parliament votes yes to NATO
  • Govt fixes tolls for Padma Bridge
    Govt fixes tolls for Padma Bridge

MOST VIEWED

  • People watch a TV broadcasting a news report on the coronavirus disease (Covid-19) outbreak in North Korea, at a railway station in Seoul, South Korea on 17 May 2022. Photo: Reuters.
    N Korea Covid outbreak could have 'devastating' impact on human rights, UN says
  • Two women hug at a closed street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 16, 2022. REUTERS/Aly Song
    Shanghai achieves 'zero Covid' status but normal life is weeks away
  • People wearing protective face masks commute amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea March 30, 2020, in this photo released by Kyodo. Picture taken March 30, 2020. Mandatory credit Kyodo/via REUTERS
    N Korea mobilises army, steps up tracing amid Covid wave
  • Customers wait in front of a restaurant in Beijing, China April 15, 2022. REUTERS/Tingshu Wang/Files
    China's economy skids as lockdowns hit factories, retailers
  • A medical worker in a protective suit collects a swab from a resident at a makeshift nucleic acid testing site inside a residential compound under lockdown, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China April 14, 2022. REUTERS/Xihao Jiang
    Shanghai aims for return to normal life from 1 June
  • South Korea's new President Yoon Suk-yeol signs a document as he works at the new Presidential office in Seoul, South Korea, May 10, 2022. Yonhap via REUTERS/File Photo
    S Korea says it will spare no effort to help North Korea amid Covid outbreak

Related News

  • Covid vaccine maker Moderna flags Japan ambition with sumo sponsorship
  • Moderna seeks FDA authorisation for second Covid booster for all adults
  • Moderna jabs to be given as boosters instead of Pfizer
  • Moderna could be ready to develop omicron booster in weeks: CEO
  • Moderna Covid-19 vaccine patent dispute headed to court, US NIH head says

Features

Despite Bangladesh having about 24,000 km of waterways, only a few hundred kilometres are covered by commercial launch services. Photo: Saad Abdullah

Utilising waterways: When common home-goers show the way

7h | Panorama
Illustration: TBS

How Putin revived Nato

9h | Panorama
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam

The United House: Living and working inside nature

9h | Habitat
Pcycle team members at a waste management orientation event. Photo: Courtesy

Pcycle: Turning waste from bins into beautiful crafts

10h | Panorama

More Videos from TBS

The first mosque in India was built Prophet Mohammad time

The first mosque in India was built Prophet Mohammad time

18m | Videos
After six decades ,the Archies is back

After six decades ,the Archies is back

18m | Videos
Exporters in discomfort, expatriates preferring Hundi

Exporters in discomfort, expatriates preferring Hundi

18m | Videos
Can your coworker be your closest friend?

Can your coworker be your closest friend?

10h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
Impact of falling taka against US dollar
Banking

Taka losing more value as global currency market volatility persists

4
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

5
Union Capital asked to return Tk100cr FDR to BATBC 
Banking

Union Capital asked to return Tk100cr FDR to BATBC 

6
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab